{"topic":{"0":"Anti-IL-6","1":"Anti-IL-6","2":"Anti-IL-6","3":"Anti-IL-6","4":"Anti-IL-6","5":"Anti-IL-6","6":"Anti-IL-6","7":"Anti-IL-6","8":"Anti-IL-6","9":"Anti-IL-6","10":"Anti-IL-6","11":"Anti-IL-6","12":"Anti-IL-6"},"dialog_lvl":{"0":"model","1":"model","2":"model","3":"model","4":"model","5":"model","6":"model","7":"model","8":"model","9":"model","10":"model","11":"model","12":"model"},"role":{"0":"Explainer","1":"Explainee","2":"Explainer","3":"Explainee","4":"Explainer","5":"Explainee","6":"Explainer","7":"Explainee","8":"Explainer","9":"Explainee","10":"Explainer","11":"Explainee","12":"Explainer"},"turn_num_tokens":{"0":12,"1":9,"2":26,"3":6,"4":18,"5":7,"6":7,"7":6,"8":30,"9":9,"10":9,"11":4,"12":15},"turn":{"0":"Hi, I'm your automated assistant. I can answer your questions about Anti-IL-6.","1":"What are some promising agents that act on IL-6?","2":"Several agents are in clinical trials: olokizumab (CDP6038) elsilimomab, BMS-945429(ALD518), sirukumab (CNTO 136), and CPSI-2364 an apparent macrophage-specific inhibitor of the p38 mitogen-activated protein kinase pathway.","3":"Are there any other promising agents?","4":"ALX-0061. e.g. for rheumatoid arthritis : clazakizumab, olokizumab, sarilumab and sirukumab have all reported encouraging phase 2 results.","5":"Are these agents in later stage trials?","6":"Sirukumab is in multiple phase 3 trials.","7":"Are there any other agents mentioned?","8":"Agents in pre-clinical development include ARGX-109, FE301, FM101 New research has found IL-6 to be an anti-inflammatory cytokine with multiple beneficial effects when released by contracting muscle as a myokine.","9":"Are there any other interesting aspects about this article?","10":"IL-6 had previously been classified as a proinflammatory cytokine.","11":"Why was it misclassified?","12":"Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage."}}